data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Puma Biotechnology
(NASDAQ:PBYI)
$2.78
-0.07[-2.46%]
At close: Jul 1
$2.78
00
After Hours: 4:30PM EDT
Day High/Low2.7 - 2.89
52 Week High/Low1.6 - 9.48
Open / Close2.88 / 2.78
Float / Outstanding36.7M / 45M
Vol / Avg.289.8K / 476.4K
Mkt Cap125M
P/E-
50d Avg. Price2.36
Div / Yield-
Payout Ratio-
EPS-0.08
Total Float36.7M

Puma Biotechnology (NASDAQ:PBYI), Quotes and News Summary

Puma Biotechnology (NASDAQ: PBYI)

Day High/Low2.7 - 2.89
52 Week High/Low1.6 - 9.48
Open / Close2.88 / 2.78
Float / Outstanding36.7M / 45M
Vol / Avg.289.8K / 476.4K
Mkt Cap125M
P/E-
50d Avg. Price2.36
Div / Yield-
Payout Ratio-
EPS-0.08
Total Float36.7M
Benzinga - Jun 6, 2022, 9:07AM
Benzinga - Jun 5, 2022, 9:03AM
Benzinga - May 26, 2022, 5:11PM
Benzinga - May 6, 2022, 12:23PM
Benzinga - May 5, 2022, 4:36PM
Benzinga - Mar 10, 2022, 8:31AM
Benzinga - Mar 3, 2022, 4:45PM
Benzinga - Mar 3, 2022, 4:12PM
Benzinga - Jan 13, 2022, 6:25AM
Benzinga - Jan 12, 2022, 4:26PM
Benzinga - Jan 12, 2022, 4:11PM
Benzinga - Dec 10, 2021, 12:08PM
Benzinga - Nov 23, 2021, 4:07PM
Benzinga - Nov 22, 2021, 6:48AM
Benzinga - Nov 20, 2021, 12:16PM
Benzinga - Nov 5, 2021, 2:24PM
load more
Sector: Health Care.Industry: Biotechnology
Puma Biotechnology Inc is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The company in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. FDA in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the US as NERLYNX.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-04
REV
Q1 2022Est.ActualSurprise
EPS-0.170-0.010 0.1600
REV45.070M45.700M630.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Puma Biotechnology Questions & Answers

Q
How do I buy Puma Biotechnology (PBYI) stock?
A

You can purchase shares of Puma Biotechnology (NASDAQ: PBYI) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Puma Biotechnology's (PBYI) competitors?
Q
What is the target price for Puma Biotechnology (PBYI) stock?
A

The latest price target for Puma Biotechnology (NASDAQ: PBYI) was reported by HC Wainwright & Co. on Friday, May 6, 2022. The analyst firm set a price target for 12.00 expecting PBYI to rise to within 12 months (a possible 331.65% upside). 4 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Puma Biotechnology (PBYI)?
A

The stock price for Puma Biotechnology (NASDAQ: PBYI) is $2.78 last updated July 1, 2022, 8:00 PM UTC.

Q
Does Puma Biotechnology (PBYI) pay a dividend?
A

There are no upcoming dividends for Puma Biotechnology.

Q
When is Puma Biotechnology (NASDAQ:PBYI) reporting earnings?
A

Puma Biotechnology’s Q2 earnings are confirmed for Thursday, August 4, 2022.

Q
Is Puma Biotechnology (PBYI) going to split?
A

There is no upcoming split for Puma Biotechnology.

Q
What sector and industry does Puma Biotechnology (PBYI) operate in?
A

Puma Biotechnology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.